
While other head lice treatments treat the lice, few are highly effective against the eggs hence repeat applications are needed to eliminate an infestation. In addition, while head lice worldwide have developed resistance to many of the available products Hatchtech’s product DeOvo™ has a novel mode of action compared to other current active ingredients meaning that there is no known cross resistance with DeOvo™. DeOvo™ is a cosmetically elegant topical lotion containing an inhibitor of metalloproteases known to impede all stages of the louse lifecycle from egg to adult. A substantial body of scientific data has established the mode of action and preclinical and clinical studies have shown DeOvo™ to be both highly effective and safe.
Hatchtech is securely financed by a consortium of specialist venture capitalists and is located in Melbourne, Australia.
May 01, 2012 Hatchtech appoints new CEO and completes financing round
Feb 15, 2012 Hatchtech Extends Patent Protection for DeOvo™ Head Lice Treatment
Dec 15, 2011 Successful completion of Hatchtech's phase 2b clinical trial in head lice
Aug 31, 2011 Hatchtech completes treatment phase of 2b clinical trial of new-generation headlice treatment DeOvo™